| Pulsipher, Michael |
NCT02963064: JSP191 Antibody Targeting Conditioning in SCID Patients |
|
|
| Recruiting | 1/2 | 40 | US | Humanized anti-CD117 Monoclonal Antibody (JSP191) | Jasper Therapeutics, Inc. | SCID | 06/25 | 06/28 | | |
AUTO1-PY1, NCT06173518: A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) |
|
|
| Recruiting | 1 | 24 | Europe, US | AUTO1, Obecabtagene autoleucel (obe-cel) | Autolus Limited | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | 11/27 | 11/27 | | |
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients |
|
|
| Available | N/A | | Canada, US, RoW | CTL019, tisagenlecleucel, Kymriah | Novartis Pharmaceuticals | Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL) | | | | |
| Ilfeld, Brian M |
NCT04341948: Treatment of Post-Operative Pain Following Orthopedic Surgery With SPRINT® Peripheral Nerve Stimulation (PNS) System |
|
|
| Completed | N/A | 56 | US | SPRINT Peripheral Nerve Stimulation (PNS) System, SPRINT, SPRINT System | SPR Therapeutics, Inc., United States Department of Defense | Postoperative Pain, Total Knee Replacement, Total Knee Arthroplasty, Partial Knee Replacement | 06/24 | 06/24 | | |
NCT06071715: Cryoanalgesia to Treat Phantom Limb Pain Following Above-Knee Amputation |
|
|
| Active, not recruiting | N/A | 12 | US | ACTIVE cryoneurolysis, cryoablation, SHAM cryoneurolysis, sham cryoablation | University of California, San Diego, Varian Medical Systems | Amputation, Surgical, Amputation, Traumatic, Phantom Limb Pain, Phantom Pain Following Amputation of Lower Limb | 11/24 | 10/25 | | |
| Urbanic, James |
CHIO3, NCT04062708: Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 38 | US | Durvalumab, Imfinzi, Surgery, Radiotherapy | Alliance Foundation Trials, LLC., AstraZeneca | Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer | 12/25 | 06/26 | | |
AFT-57, NCT05798663: Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC |
|
|
| Recruiting | 2 | 178 | US | Atezolizumab, Tecentriq, L01XC32, Tiragolumab | Alliance Foundation Trials, LLC., Genentech, Inc. | NSCLC | 08/25 | 10/27 | | |
| Reid, Erin G |
NCT03893682: A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas |
|
|
| Active, not recruiting | 1 | 160 | US | CG-806, Luxeptinib | Aptose Biosciences Inc. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma | 12/24 | 05/25 | | |
| Tzachanis, Dimitrios |
| Recruiting | 2 | 110 | US | zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine, Bendamustine | Miltenyi Biomedicine GmbH | Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Lymphoma, Central Nervous System Lymphoma | 12/24 | 12/26 | | |
NCT03680092: Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation |
|
|
| Active, not recruiting | 2 | 43 | US | Cyclophosphamide, cytophosphane, Cytoxan, Neosar, abatacept, ORENCIA, Methotrexate, Trexall, Tacrolimus, Prograf, Astagraf XL, Envarsus XR | Dimitrios Tzachanis, MD PhD, Bristol-Myers Squibb | GVHD, Hematologic Neoplasms | 06/23 | 12/27 | | |
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients |
|
|
| Available | N/A | | Canada, US, RoW | CTL019, tisagenlecleucel, Kymriah | Novartis Pharmaceuticals | Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL) | | | | |
| Leonard, Stephanie |
| Recruiting | 2 | 230 | Europe, Canada, US | DBV1605 | DBV Technologies | Cow's Milk Allergy | 03/24 | 03/24 | | |
| Active, not recruiting | 1/2 | 264 | US, RoW | STMC-103H, Placebo | Siolta Therapeutics, Inc. | Atopic Dermatitis, Type 1 Hypersensitivity | 11/24 | 10/25 | | |
| Laubach, Susan |
NCT03878069: Registry Study of Revcovi Treatment in Patients With ADA-SCID |
|
|
| Completed | N/A | 32 | US | elapegademase-lvlr, Revcovi | Chiesi Farmaceutici S.p.A. | Adenosine Deaminase Severe Combined Immunodeficiency | 01/23 | 01/23 | | |
| Santiago-Lastra, Yahir |
| Recruiting | N/A | 28 | US | Glean Urodynamics System, GUS | Bright Uro, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Urologic Diseases, Urodynamics | 06/25 | 06/25 | | |
| Campos-Ruiz, David |
NCT04636229: Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee |
|
|
| Active, not recruiting | 3 | 474 | US | Amniotic Suspension Allograft, Placebo | Organogenesis, Premier Research Group plc | Knee Osteoarthritis | 07/23 | 03/24 | | |
NCT05603754: A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES) |
|
|
| Completed | 3 | 496 | US | Lorecivivint, SM04690, Placebo, Vehicle | Biosplice Therapeutics, Inc., NBCD A/S | Knee Osteoarthritis | 02/24 | 02/24 | | |
| Active, not recruiting | 1 | 67 | US | GNSC-001, sc-rAAV2.5IL-1Ra, transient immune-modulation, Placebo | Genascence Corporation, California Institute for Regenerative Medicine (CIRM) | Osteoarthritis, Knee, Osteo Arthritis Knee, Knee Osteoarthritis | 05/25 | 05/29 | | |
| Silva, Jayamalee De |
| No trials found |
| Jimenez, Edith |
| No trials found |
